1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,022 | 0,023 | 08:41 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 12.02. | Genflow meldet positive Zwischenergebnisse bei Gentherapie-Studie mit Hunden | 23 | Investing.com Deutsch | ||
| 12.02. | Genflow reports positive interim results from dog gene therapy trial | 1 | Investing.com | ||
| 12.02. | Genflow Biosciences PLC Announces Preliminary Interim Results From Dog Study | 160 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 12.02. | Genflow Biosciences - Preliminary Interim Results From Dog Study | - | RNS | ||
| 11.02. | Genflow Biosciences to seek approval for potential equity raise | 4 | Investing.com | ||
| 11.02. | Genflow Biosciences strebt Zustimmung für potenzielle Kapitalerhöhung an | - | Investing.com Deutsch | ||
| 11.02. | Genflow Biosciences PLC Announces Notice of GM | 193 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 11.02. | Genflow Biosciences - Notice of GM | - | RNS | ||
| 30.01. | Genflow Biosciences PLC Announces Holding(s) in Company | 257 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / January 30, 2026 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen | |
| 28.01. | Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities | 157 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / January 28, 2026 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION... ► Artikel lesen | |
| 28.01. | Genflow Biosciences - Administrative Approval of Grant & 2026 Priorities | - | RNS | ||
| 19.01. | EXECUTIVE CHANGES: Genflow Biosciences names Berdugo as new chair | 1 | Alliance News | ||
| 19.01. | Genflow Biosciences PLC Announces Directorate Change | 253 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 19.01. | Genflow Biosciences appoints new chairman to lead expansion | 2 | Investing.com | ||
| 19.01. | Genflow Biosciences - Directorate change | 2 | RNS | ||
| 08.01. | TRADING UPDATES: Genflow Biosciences lays out hopes for 2026 | 1 | Alliance News | ||
| 08.01. | Genflow: Gentherapie-Studie bei Hunden ohne unerwünschte Ereignisse | 1 | Investing.com Deutsch | ||
| 08.01. | Genflow reports no adverse events in dog aging gene therapy trial | 1 | Investing.com | ||
| 08.01. | Genflow Biosciences - Review of 2025 | - | RNS | ||
| 16.12.25 | Genflow Biosciences PLC: Genflow Completes Dosing Phase of Canine Gene Therapy Trial | 314 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 48,600 | +0,83 % | CRISPR Therapeutics-Aktie: Goldgrube oder Kapitalvernichtung? | Wir sind bekennende GARP-Anhänger (Growth at a Reasonable Price). Nicht aus Prinzip, sondern aus Erfahrung. Wachstum ja - aber bitte nicht um jeden Preis. Wir haben in den letzten zwanzig Jahren genug... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,427 | +1,55 % | PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research | ||
| DENALI THERAPEUTICS | 17,975 | -1,07 % | Wolfe Research initiates Denali Therapeutics stock with Peerperform | ||
| VOYAGER THERAPEUTICS | 3,176 | -0,94 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| BIOAGE LABS | 18,700 | +2,19 % | Oppenheimer initiates BioAge Labs stock coverage with outperform rating | ||
| LINEAGE CELL THERAPEUTICS | 1,500 | -1,96 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien | ||
| BIOPHYTIS | 0,054 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.12.2025 | Das Instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM. EO -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 09.12.2025 und ex Kapitalmassnahme am 10.12.2025 The instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM.... ► Artikel lesen | |
| SERINA THERAPEUTICS | 1,380 | -2,13 % | Serina Therapeutics, Inc.: Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease | - First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1- Company remains on track for... ► Artikel lesen | |
| LONGEVERON | 0,564 | 0,00 % | Longeveron Appoints Stephen H. Willard as Chief Executive Officer | Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant... ► Artikel lesen | |
| ARCELLX | 113,73 | -0,03 % | Aktien New York Ausblick: Leichte Verluste nach Trumps Zollankündigung | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Montag vor dem Hintergrund neuer Zollunsicherheit auf einen etwas tieferen Handelsauftakt zu. Nachdem der Oberste Gerichtshof der USA dem Präsidenten Donald... ► Artikel lesen | |
| QIAGEN | 41,120 | 0,00 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Qiagen nach Gesprächen mit dem Management in Boston mit einem Kursziel von 59 US-Dollar auf "Buy" belassen. Die Wettbewerbssorgen im Zusammenhang... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,180 | +5,69 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,490 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,76 | -0,22 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders | SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of... ► Artikel lesen | |
| BEAM THERAPEUTICS | 32,290 | 0,00 % | Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street | $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated... ► Artikel lesen |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,021 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.